Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model

Item
http://www.wikidata.org/entity/Q34761156
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?Myeloid-derived suppressor cells as therapeutic target in hematological malignanciesThe cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.Adoptive Cell Therapy in Multiple Myeloma.Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.Activation of iNKT Cells Prevents Salmonella-Enterocolitis and Salmonella-Induced Reactive Arthritis by Downregulating IL-17-Producing γδT Cells.Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma.Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
P2860

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model

Item
http://www.wikidata.org/entity/Q34761156
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@ast
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@en
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@nl
type
label
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@ast
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@en
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@nl
prefLabel
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@ast
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@en
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Preclinical evaluation of inva ...... he 5T33 multiple myeloma model
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0065075
P407
P433
P478
P50
P577
P5875
P698
P932